Editas Medicine announces preclinical success for EDIT401 with over 90 percent LDL cholesterol reduction in animal models
Reuters
Oct 09
<a href="https://laohu8.com/S/EDIT">Editas Medicine</a> announces preclinical success for EDIT401 with over 90 percent LDL cholesterol reduction in animal models
Editas Medicine Inc. has announced preclinical proof-of-concept data for its experimental therapy EDIT-401, which is designed to significantly reduce LDL-cholesterol (LDL-C). The results were presented at the 32nd Annual European Society of Gene and Cell Therapy (ESGCT) Congress. In preclinical studies involving non-human primates and mouse models, EDIT-401 achieved a mean reduction of at least 90% in LDL-C levels following a single dose, with effects maintained in mouse models over a three-month period. The therapy uses a CRISPR/Cas9-based approach to upregulate the LDL receptor (LDLR) by disrupting negative regulatory elements, leading to increased LDLR protein in the liver. The results were shared in an oral presentation by Editas Medicine's Chief Scientific Officer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9542614-en) on October 09, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.